

Enfortumab EV-302/KN-A39

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Enfortumab EV-302/KN-A39

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: FDA: Enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. EMA:

Pembrolizumab, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.

Experimental Arm: Enfortumab + Pembrolizumab

Control Arm: Platinum-based ChT



